Compare trial endpoint was major adverse cardiac events (MACE) at two years, which is a composite of all death, non-fatal heart attack (myocardial infarction or MI) and target vessel revascularisation (TVR), for which, Xience V showed a 34% lower incidence of MACE compared to TAXUS (9.0% for Xience V vs 13.7% for TAXUS).
The composite secondary endpoint of cardiac death, non-fatal MI and target lesion revascularisation (TLR) resulted in a 35% lower incidence for Xience V compared to TAXUS (7.4% for Xience V vs 11.4% for TAXUS).
Additionally, the stent thrombosis rate for Xience V between one and two years increased from 0.7% at one year to 0.9% at two years, while the TAXUS arm increased from 2.6% at one year to 3.9% at two years.
Abbott Vascular chief medical officer and Medical Affairs divisional vice president Charles Simonton said that the Compare results show that the gap in stent thrombosis rates between Xience V and TAXUS Liberte widened from 1.9% at one year to 3.0% at two years.
“The Compare investigators have provided some of the first major insights into the comparative long-term differences in stent thrombosis rates between one and two years for different stent platforms,” Simonton said.
Abbott Vascular senior vice president Robert Hance said that the two-year results presented today for the Compare trial and for the SPIRIT IV trial demonstrate impressive outcomes for Xience V compared to TAXUS Liberte and TAXUS Express, respectively.
“Both of these trials show the differences in the performance of these drug eluting stents and add to the safety and efficacy data for Xience V,” Hance said.
